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Abstract
Background: Acute pancreatitis in pregnancy (APIP) is a life-threatening disease 
for both mother and fetus. To date, only three patients with recurrent hypertriglyc-
eridemia-induced APIP (HTG-APIP) have been reported to carry rare variants in 
the lipoprotein lipase (LPL) gene, which encodes the key enzyme responsible for 
triglyceride (TG) metabolism. Coincidently, all three patients harbored LPL variants 
on both alleles and presented with complete or severe LPL deficiency.
Methods: The entire coding regions and splice junctions of LPL and four other 
TG metabolism genes (APOC2, APOA5, GPIHBP1, and LMF1) were analyzed by 
Sanger sequencing in a Han Chinese patient who had experienced two episodes of 
HTG-APIP. The impact of a novel LPL missense variant on LPL protein expression 
and activity was analyzed by transient expression in HEK293T cells.
Results: A novel heterozygous LPL missense variant, p.His210Leu (c.629A > T), 
was identified in our patient. This variant did not affect protein synthesis but signifi-
cantly impaired LPL secretion and completely abolished the enzymatic activity of 
the mutant protein.
Conclusion: This report describes the first identification and functional characteriza-
tion of a heterozygous variant in the LPL that predisposed to recurrent HTG-APIP. 
Our findings confirm a major genetic contribution to the etiology of individual pre-
disposition to HTG-APIP.
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1 |  INTRODUCTION
Acute pancreatitis in pregnancy (APIP) is a life-threaten-
ing disease for both mother and fetus, with an incidence 
of 1 in 1,000–10,000 pregnancies (Igbinosa, Poddar, & 
Pitchumoni, 2013; Zhang et al., 2013). Over the past de-
cades, significant improvements in diagnosis and manage-
ment have reduced the mortality rate from 37% to 3.3% 
for mothers and from 60% to 11.6% for the fetus, respec-
tively (Ducarme, Maire, Chatel, Luton, & Hammel, 2014; 
Fan et al., 2018; Ramin, Ramin, Richey, & Cunningham, 
1995; Tang, Xu, Song, Mei, & Zhang, 2018; Vilallonga, 
Calero-Lillo, Charco, & Balsells, 2014; Xu, Wang, & 
Zhang, 2015). Gallstones are the leading cause of APIP 
worldwide while hypertriglyceridemia (HTG) ranks sec-
ond in China and third in Western countries, respectively 
(Luo et al., 2018; Papadakis, Sarigianni, Mikhailidis, 
Mamopoulos, & Karagiannis, 2011). Compared to biliary 
APIP, HTG-induced APIP (HTG-APIP) often has a more 
severe disease course, is associated with a poorer out-
come, and causes more maternal and fetal deaths (Deng, 
Wang, Wu, Tang, & Chen, 2014; Liu, Lun, Lv, Hou, & 
Wang, 2016; Luo et al., 2018; Sun, Fan, & Wang, 2013; 
Tang et al., 2018).
A normal triglyceride (TG) level is less than 
1.7 mmol/L (150 mg/dl). During the late stages of ges-
tation, the maternal TG concentration normally in-
creases two- to fourfold due to a high-fat diet, lack of 
exercise, increase in estrogen, and other factors (Alvarez, 
Montelongo, Iglesias, Lasuncion, & Herrera, 1996; 
Basaran, 2009). However, the TG level in HTG-APIP pa-
tients can increase to more than 11.3 mmol/L (1,000 mg/
dl), the threshold for defining severe HTG (Garg, Garg, 
Hegele, & Lewis, 2019), which may be determined by 
genetic factors associated with TG metabolism. In this 
regard, variants in the lipoprotein lipase (LPL) gene 
(OMIM# 609708), which encode the key enzyme respon-
sible for TG metabolism, have been reported in a dozen 
of HTG-APIP patients (Bartha et al., 2009; Gilbert, 
Rouis, Griglio, de Lumley, & Laplaud, 2001; Goldberg 
& Hegele, 2012; Hieronimus, Benlian, Bayer, Bongain, 
& Fredenrich, 2005; Keilson, Vary, Sprecher, & Renfrew, 
1996; Liu et al., 2016; Ma et al., 1993, 1994; Murugasu 
et al., 1998; Suga et al., 1998; Xie et al., 2015). Of 
these patients, only three had experienced a recurrence 
of HTG-APIP. Interestingly, all three of these recurrent 
HTG-APIP patients harbored LPL variants on both alleles 
and exhibited either no or very low-plasma post-heparin 
LPL activity (Liu et al., 2016; Murugasu et al., 1998; 
Suga et al., 1998). Herein, we report the first identifi-
cation and functional characterization of a heterozygous 
variant in the LPL predisposing to recurrent HTG-APIP.
2 |  MATERIALS AND METHODS
2.1 | Ethical compliance
This study was approved by the Ethics Committee of Jinling 
Hospital. Informed consent was obtained from all participants.
2.2 | Patient
The patient is of Han Chinese origin. She had been pregnant 
twice and had suffered from HTG-APIP during each pregnancy.
The patient experienced her first episode of acute pancreati-
tis at 40(+1) weeks of gestation in 2012 (at the age of 26), with 
a fasting TG level of 12.55 mmol/L (1,104.2 mg/dl) (Figure 1). 
She underwent emergency cesarean section and a healthy baby 
girl was delivered with an Apgar score of 10. About 200 ml 
chylous ascites were drained from her abdominal cavity during 
the cesarean delivery. The severity of the pancreatitis was mild 
in accordance with the Atlanta criteria (Banks et al., 2013). 
The patient was successfully managed with fasting, and was 
discharged 11 days after delivery without any complications.
The second attack of acute pancreatitis occurred at 37(+2) 
weeks of pregnancy in 2017 (at the age of 31), with an even 
higher fasting TG level, namely 20.1  mmol/L (1,777.9  mg/
dl), being observed (Figure 1). Again she underwent cesarean 
section; a healthy baby boy was delivered with an Apgar score 
of 10. Once again, chylous ascites (300 ml) were drained from 
the abdominal cavity. The patient was treated with fasting, gas-
trointestinal decompression, inhibition of acid and enzyme se-
cretion, and fluid therapy in an intensive care unit but had a 
persistent fever (38.5°C–4°C) beginning 7 days after delivery. 
She was therefore transferred to the Surgical Intensive Care Unit 
(SICU) at Nanjing, the largest acute pancreatitis therapy center 
in Southern China, for further treatment at 22 days after deliv-
ery, by which time her fasting serum TG level had decreased to 
a borderline high level (i.e., 2.1 mmol/L (185.94 mg/dl)).
In our center, the patient was diagnosed with severe 
acute pancreatitis exacerbated by infected pancreatic necro-
sis (Figure 2a). She was treated twice with computer tomog-
raphy-guided percutaneous peritoneal drainage (Figure 2b), 
10 days of tigecycline administration, and one procedure of 
endoscopic removal of necrotic pancreatic tissue, followed 
by enteral nutrition and parenteral nutrition. By 66  days 
after delivery, the patient's physical condition had improved 
remarkably and she was started on an oral fluid diet. Two 
days later, the patient was transferred to our rehabilitation 
center for further recovery. After 40 more days, the patient 
was discharged from our hospital, with the peripancreatic 
exudation and necrosis being greatly reduced (Figure 2c).
Finally, it is important to note that the patient's serum TG level 
was in the normal range (ranging from 0.8 to 1.3 mmol/L) without 
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taking medications between the two episodes of acute pancreatitis 
and from the end of 2017 to the end of 2018 (Figure 1).
2.3 | Plasma lipid profile analysis
A blood sample was taken from the patient after fasting for 12 hr. 
Serum TG and other lipid levels were measured enzymatically 
on an automatic analyzer (Hitachi High-Tech, 7600–120).
2.4 | Variant screening
Genomic DNA was extracted from peripheral blood cells using 
the Gentra Puregene Blood kit (Qiagen) according to the manu-
facturer's instructions. All exons and splicing junctions of the 
LPL as well as the four other canonical TG metabolism genes, 
namely APOC2 (OMIM# 608083), APOA5 (OMIM# 606368), 
LMF1 (OMIM# 611761), and GPIHBP1 (OMIM# 612757), 
were amplified from genomic DNA, and analyzed by Sanger 
sequencing (Chen et al., 2019). The identified variants were 
confirmed by independent PCR amplification and sequencing.
2.5 | Reference sequence and 
variant nomenclature
NM_000237.3 and NC_000008.11 were employed as the 
LPL mRNA and genomic reference sequences, respectively. 
Nomenclature for the description of LDL variants was in ac-
cordance with the recommendations of the Human Genome 
Variation Society (HGVS) (den Dunnen et al., 2016).
2.6 | In silico analysis
The Combined Annotation-Dependent Depletion (CADD) 
tool (Kircher et al., 2014) and the PP3 rule established by 
VarSome (Kopanos et al., 2019) were employed to predict 
the pathogenicity of the LPL missense variant detected. 
CADD integrates more than 60 diverse annotations into a sin-
gle measure (C-score) for each variant, with a C-score of >20 
being regarded as evidence of pathogenicity. VarSome's PP3 
rule was based upon a combined consideration of predictions 
from 10 in silico programs, namely DANN, MutationTaster, 
dbNSFP.FATHMM, MetaSVM, MetaLR, GERP, LRT, 
MutationAssessor, PROVEAN, and SIFT.
2.7 | Analysis of LPL mass and activity 
in the patient's plasma
A blood sample was collected from the patient after overnight 
fasting and 10  min after an intravenous injection of heparin 
(60 IU/kg body weight). Blood plasma was then prepared by cen-
trifugation at 400 g for 30 min. Plasma LPL mass was determined 
with a human LPL Elisa kit (TSZ Biological Trade). Plasma 
total lipase activity and plasma hepatic lipase activity were both 
F I G U R E  1  Timeline of the patient's two episodes of hypertriglyceridemia-induced acute pancreatitis during pregnancy and her triglyceride 
(TG) levels. Note that (i) only some of the treatment procedures adopted have been illustrated and (ii) the patient was transferred to the Surgical 
Intensive Care Unit (SICU) at Nanjing on the 5 July 2017. AP, acute pancreatitis; EN, enteral nutrition; PN, parenteral nutrition
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determined using a Free Fatty Acid (FFA) assay kit (Wako kit, 
NEFA-HR(2)). In the case of the plasma hepatic lipase activity 
assay, the sample was pretreated with 1 M NaCl and incubated 
for 60 min at 4°C to inactivate the LPL. Plasma LPL activity was 
then calculated by subtracting total lipase activity from hepatic 
lipase activity. All assays were performed in triplicate.
2.8 | Cell culture and transfection
Human wild-type and mutant LPL cDNAs were synthesized 
and cloned into the pcDNA3.1 vector by GeneArt Gene 
Synthesis (Vigene Biosciences), and confirmed by DNA se-
quencing. HEK293T (ATCC, CRL-3216) cells, which have 
no endogenous LPL expression, were cultured in DMEM 
medium with 10% FBS and 1% PS at 37°C in a humidified 
chamber supplemented with 5% CO2. Transfection was per-
formed using Lipofectamine 3,000 (Thermo, L3000015) in 
6-well plates (Costar, 3,516) according to the manufacturer's 
instructions. Six hours after transfection, the medium was 
changed into fresh DMEM with 2% FBS and the cells were 
then cultured for 48 hr before LPL mass and activity analy-
sis. In the case of heparin treatment, the medium was fur-
ther changed to a 500-µl heparin-DMEM mixture (the ratio 
of DMEM and heparin is 500:8, heparin is 20 units/ml) per 
well, and the cells were cultured for an additional 30 min.
2.9 | Analysis of LPL mass and activity in 
transfected cell medium and lysate
The transfected cell medium was centrifuged to remove cells 
and cell debris, and stored at −20°C for later analysis. The 
transfected cells were treated by RIPA Lysis Buffer (Beyotime, 
China, P0013) and centrifuged at 4°C for 10 min at 12,000 g; 
the resulting supernatant was stored at −20°C for later analysis.
The expression of LPL protein in cell medium and lysate was 
analyzed by Western blot. The antibodies used were as listed 
below: 1:200 primary rabbit LPL antibodies (Cell Signaling 
Technology), 1:5000 primary mouse GAPDH antibody (Santa 
Cruz Biotechnology), 1:2000 secondary anti-mouse, and 1:5000 
anti-rabbit HRP-conjugated IgGs (Santa Cruz Biotechnology). 
Band intensities were quantified using the ImageJ software.
LPL activity in cell medium and lysate was determined using 
the abovementioned FFA assay (Wako kit, NEFA-HR(2)).
3 |  RESULTS
3.1 | Genetic findings
We analyzed the entire coding regions and proximal flanking 
intronic sequences of the LPL, APOC2, APOA5, GPIHBP1, 
and LMF1 in the patient by means of Sanger sequencing. We 
focused on the rare coding variants that resulted in missense, 
frameshift, or nonsense mutations and rare intronic variants that 
altered canonical splice sites. Rare variants are defined here as 
having an allele frequency of <1% in the East Asian population 
according to the gnomAD database (Lek et al., 2016). We iden-
tified only one such variant, c.629A > T, in exon 5 of the LPL, 
which was predicted to result in a missense variant, p.His210Leu 
(Figure 3a). This variant is absent from the gnomAD database, 
has not been previously reported in the literature, and was also 
not found in any of our other 28 Chinese HTG-APIP patients.
3.2 | Pathogenicity prediction
The histidine residue at LPL amino acid position 210 is highly 
conserved from zebrafish (Danio rerio) to humans (Figure 3b). 
Moreover, leucine, an aliphatic and uncharged residue, is signif-
icantly different from histidine, a polar and positively charged 
F I G U R E  2  Computer tomography images of the patient taken during her second episode of hypertriglyceridemia-induced acute pancreatitis 
during pregnancy. (a) Image taken upon the patient's admission to our service. Arrows indicate walled-off pancreatic necrosis. (b) Image showing 
puncture and drainage of accumulated fluid in the affected pancreas under computer tomography guidance. Arrow indicates the puncture needle. (c) 
Image taken at discharge from our hospital. Peripancreatic fluid collection and necrosis were greatly reduced (arrows)
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residue, in terms of physicochemical properties. Taken together, 
these observations suggest that the p.His210Leu missense vari-
ant is highly likely to affect LPL protein structure and func-
tion. Indeed, it was predicted to be pathogenic by both CADD 
(C-score, 26.2) and VarSome (in accordance with its PP3 rule).
3.3 | Analysis of LPL mass and activity 
in the patient's plasma
Plasma LPL mass and activity were measured when the 
patient was admitted to our center. Her LPL mass was de-
termined to be 185.7  ±  12.49  U/L, approximately half of 
the mean value of 10 normal controls (382  ±  75.62  U/L). 
Her LPL activity was 0.071  ±  0.025  mEq  L−1  hr−1, ap-
proximately 60% of the mean value of 10 normal controls 
(0.118 ± 0.055 mEq L−1 hr−1).
3.4 | In vitro functional 
characterization of the LPL missense variant
The LPL wild-type and p.His210Leu mutant coding sequences 
were transiently expressed in HEK293T cells. We first com-
pared LPL expression levels in cell lysates and media of wild-
type and mutant transfected cells with heparin treatment by 
means of Western blotting. Exogenous heparin triggers the re-
lease of cell surface-bound LPL into the medium. Significantly 
higher LPL expression was found in the cell lysate but signifi-
cantly lower LPL expression was noted in the medium of the 
mutant transfected cells as compared to those of the wild-type 
transfected cells (Figure 4). These results indicated that the 
p.His210Leu variant greatly reduced LPL secretion. We then 
compared LPL expression levels in the cell lysates of wild-type 
and mutant transfected cells without heparin treatment, finding 
no significant difference (Figure 5). This latter finding indicated 
that the p.His210Leu variant has no effect on LPL synthesis.
By contrast, LPL activity was not detectable in either the 
cell lysate or the medium of mutant vector-transfected cells with 
heparin treatment. This indicated that the p.His210Leu variant 
completely abolished the enzymatic activity of the mutant LPL 
protein. For comparison, LPL activities in the cell lysate and 
medium of wild-type transfected cells with heparin treatment 
were 0.35 ± 0.24 mEq L−1 hr−1 and 0.33 ± 0.19 mEq L−1 hr−1.
4 |  DISCUSSION
In the present study, we identified a novel heterozy-
gous LPL missense variant, p.His210Leu (c.629A > 
T), in a Chinese patient with recurrent HTG-APIP. The 
F I G U R E  3  The novel LPL missense variant found in the patient. (a) Sanger sequencing electropherogram showing the heterozygous A > 
T substitution at position c.629 of the LPL (indicated by arrow) that would be predicted to change the CAC codon for histidine at position p.210 
(underlined) to a CTC codon specifying leucine (i.e., p.His210Leu). Upper panel, patient. Lower panel, a healthy control. (b) Alignment of LPL 
amino acid sequences from a range of vertebrates illustrating the strict evolutionary conservation of histidine at residue 210
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pathogenicity of this variant was supported by predictions 
made using CADD and VarSome, then demonstrated by 
virtue of the significantly reduced LPL mass and activity in 
the patient's plasma (compared to that of normal controls), 
and finally confirmed by in vitro functional analyses. The 
in vitro analysis demonstrated that the p.His210Leu mis-
sense variant did not affect protein synthesis but signifi-
cantly impaired LPL secretion and completely abolished 
enzymatic activity of the mutant protein. It should be noted 
that two other missense variants, p.His210Asp (c.628C > 
G) and p.His210Arg (c.629A > G), have been reported in 
LPL amino acid residue 210. p.His210Asp also caused a 
complete loss of LPL activity when tested in vitro (Holzl 
et al., 2000). However, in vitro protein analysis was not 
performed on this variant and no data on plasma LPL mass 
in the carrier were available. Therefore, it remains unclear 
whether the complete loss of enzyme activity caused by the 
p.His210Asp missense variant is due to its impact on enzy-
matic activity or alternatively whether it exerts its effects 
on protein synthesis and/or secretion. p.His210Arg was not 
functionally characterized in vitro; however, the patient, 
who was homozygous for this variant, exhibited a LPL 
activity deficiency but a LPL mass value within the nor-
mal range (Ariza et al., 2018). In short, all three missense 
variants caused a complete or almost complete functional 
loss of the affected allele, highlighting the importance of 
the evolutionarily strictly conserved residue 210 for LPL 
structure and function. In this regard, it is pertinent to note 
that based upon the LPL crystal structure, “the active site 
cleft is lined by the hydrophobic side chains of W82, V84, 
W113, Y121, Y158, L160, A185, P187, F212, I221, F239, 
V260, V264, and K265, which would form van der Waals 
interactions with (and stabilize) the hydrophobic tails of 
lipid substrates in the active site” (Birrane et al., 2019). 
The spatial proximity of residue 210 to these active site-
defining residues or structures speaks for itself.
As mentioned earlier, only three patients with recurrent 
HTG-APIP have so far been reported to carry rare LPL vari-
ants (Liu et al., 2016; Murugasu et al., 1998; Suga et al., 1998). 
Coincidentally, all three patients had severe LPL deficiency 
and were each found to have two affected LPL alleles. One 
patient, who had complete LPL deficiency, was homozygous 
for a nonsense variant, p.Trp409* (c.1227G > A) (Suga et al., 
1998); one patient, with almost complete LPL deficiency, was 
homozygous for a missense variant, p.Cys291Tyr (c.872G 
> A) (Murugasu et al., 1998); and the third patient, whose 
post-heparin LPL activity was <17% that of normal controls, 
was compound heterozygous for p.Glu269Lys (c.805G > 
A) and p.Leu279Val (c.835C > G) (Liu et al., 2016). The 
p.Trp409* homozygous patient, when not pregnant, managed 
to maintain a mild HTG state with a plasma TG level ranging 
from 5.6 to 11.3 mmol/L by ingesting a low-fat diet (Suga 
F I G U R E  4  Western blot analysis of 
LPL expression in cell lysates (a) and media 
(b) of transfected human embryonic kidney 
(HEK293T) cells treated with heparin, 
whose role was to release LPL into the cell 
medium. In each panel, a representative 
blot is shown on the left while the LPL 
expression level in the p.His201Leu mutant 
vector-transfected cells relative to that in the 
wild-type vector-transfected cells is shown 
on the right. Results were the average taken 
from three independent experiments. EV, 
empty vector; mut, mutant; wt, wild-type. 
GPDAH was used as a loading control. 
*p < .05; **p < .01
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et al., 1998); after discharge, the compound heterozygous 
[p.Glu269Lys and p.Leu279Val] patient maintained a consis-
tently elevated TG level (ranging from 7 to 11 mmol/L) by 
following a lipid-lowering drug regimen (Liu et al., 2016); 
finally, in the case of the p.Cys291Tyr homozygous patient, 
her TG level at 4 weeks postpartum (25.5 mmol/L) exhibited 
no significant decrease by comparison to that measured at 
18 weeks of gestation (29.6 mmol/L) (Murugasu et al., 1998). 
By contrast, our patient was characterized by a much higher 
post-heparin LPL activity (i.e., ~50% of normal controls), 
harbored a heterozygous LPL missense variant that led to the 
complete functional loss of the affected allele, but exhibited 
normal TG levels in the follow-up periods without taking 
any medication. This notwithstanding, it is clear that LPL 
variants, whether heterozygous, compound heterozygous, or 
homozygous, can predispose to recurring HTG-APIP. In this 
regard, it is also worth mentioning that the development of 
severe HTG in pregnancy could also be ascribed to polygenic 
inheritance (Dron et al., 2019). Under the pregnancy meta-
bolic setting, a combination of variants in many genes may 
raise plasma TG with various mechanisms related or not to 
LPL.
In our patient, her second episode of HTG-APIP was as-
sociated with a higher peak TG level, an increase in chylous 
ascites, and more severe pancreatitis as compared to the first 
episode experienced. It also appears that TG levels in all three 
previously reported HTG-APIP patients tended to be higher 
in later episodes of the disease than the earlier ones (Liu et 
al., 2016; Murugasu et al., 1998; Suga et al., 1998). These 
findings are consistent with recent observations suggesting 
that (a) an episode of acute pancreatitis may predispose to 
the risk of developing more severe metabolic derangements 
(Singh et al., 2018) and (b) more severe HTG may result in 
more severe disease (Jo et al., 2019).
There is one final point to make. Our patient bore two 
healthy children owing to timely cesarean section. It fol-
lows that early diagnosis and clinical intervention are vi-
tally important to acute pancreatitis patients caused by 
gestational HTG and should help to improve the prognosis 
of the fetus.
5 |  CONCLUSIONS
The present study describes the first identification and func-
tional characterization of a heterozygous variant in the LPL 
that predisposed to recurrent HTG-APIP. Our findings not 
only underscore the importance of genetic defects in predis-
posing to HTG and/or acute pancreatitis but also shed new 
light on the complexity underlying the etiology of these 
phenotypes.
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